Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.
Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, Cinieri S, Curigliano G, Del Mastro L, De Placido S, Fabi A, Fortunato L, Generali D, Gennari A, Gori S, Grandi G, Guarneri V, Klinger M, Livi L, Marchiò C, Palumbo I, Panizza P, Pravettoni G, Pruneri G, Puglisi F, Sapino A, Tinterri C, Turchetti D, De Laurentiis M. Zambelli A, et al. Among authors: de placido s. Cancer Treat Rev. 2024 Nov;130:102815. doi: 10.1016/j.ctrv.2024.102815. Epub 2024 Aug 21. Cancer Treat Rev. 2024. PMID: 39208751 Free article. Review.
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.
Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V. Miglietta F, et al. Among authors: de laurentis m, de placido s. Cancer Treat Rev. 2023 Mar;114:102511. doi: 10.1016/j.ctrv.2023.102511. Epub 2023 Jan 6. Cancer Treat Rev. 2023. PMID: 36638600 Free article. Review.
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511].
Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentiis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V. Miglietta F, et al. Among authors: de placido s, de laurentiis m. Cancer Treat Rev. 2023 Jun;117:102570. doi: 10.1016/j.ctrv.2023.102570. Epub 2023 May 5. Cancer Treat Rev. 2023. PMID: 37150120 Free article. No abstract available.
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511].
Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentiis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V. Miglietta F, et al. Among authors: de placido s, de laurentiis m. Cancer Treat Rev. 2023 Sep;119:102594. doi: 10.1016/j.ctrv.2023.102594. Epub 2023 Jul 1. Cancer Treat Rev. 2023. PMID: 37400291 Free article. No abstract available.
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.
Criscitiello C, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, Castellan L, Arpino G, Conte P, Di Meco F, Gennari A, Guarneri V, Visani L, Livi L, Marchetti P, Puglisi F, Viale G, Del Mastro L, De Placido S, Curigliano G. Criscitiello C, et al. Among authors: de placido s, de laurentiis m. Cancer Treat Rev. 2023 Nov;120:102618. doi: 10.1016/j.ctrv.2023.102618. Epub 2023 Aug 22. Cancer Treat Rev. 2023. PMID: 37639757 Review.
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G. Gerratana L, et al. Among authors: de placido s, de santo i, de laurentiis m. Cancer Treat Rev. 2018 Jul;68:102-110. doi: 10.1016/j.ctrv.2018.06.005. Epub 2018 Jun 11. Cancer Treat Rev. 2018. PMID: 29940524 Free article. Review.
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G, Fabi A, Bighin C, Riccardi F, Cianniello D, De Laurentiis M, Puglisi F, Pelizzari G, Bonotto M, Russo S, Frassoldati A, Pazzola A, Montemurro F, Lambertini M, Guarneri V, Cognetti F, Locci M, Generali D, Conte P, De Placido S, Giuliano M, Arpino G, Del Mastro L. Schettini F, et al. Among authors: de placido s, de placido p, de laurentiis m. ESMO Open. 2021 Apr;6(2):100099. doi: 10.1016/j.esmoop.2021.100099. Epub 2021 Apr 2. ESMO Open. 2021. PMID: 33819752 Free PMC article.
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Criscitiello C, et al. Among authors: de placido s, de laurentiis m. Eur J Surg Oncol. 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. Eur J Surg Oncol. 2015. PMID: 26238477 Review.
398 results